PD-L1 as a Novel Mediator of Lung Fibroblast to Myofibroblast Transition

Idiopathic pulmonary fibrosis (IPF) is an incurable disease that affects approximately 3 million people worldwide. Although two drugs (nintedanib and pirfenidone) have been approved for treatment of IPF, currently there is a lack of effective pharmacotherapy that could stop the progression or offer a cure for this devasting disease.